Domain Therapeutics enters into a new collaboration agreement with Pfizer Inc. to profile signaling pathways of GPCRs across multiple diseases
- French biotech company will use its bioSens-AllTM proprietary technology to correlate impact of GPCR mutations on signaling pathways
- Results may constitute guidance for future drug discovery programs
Strasbourg, France, September 1, 2020 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, neurology and rare diseases, announces today the signing of a collaboration agreement with Pfizer Inc. (Pfizer;NYSE:PFE). The collaboration aims to profile downstream signaling pathways of a set of GPCRs potentially involved across multiple therapeutic areas, using Domain’s bioSens-AllTM technology consisting of BRET based cellular assays enabling them to investigate native form of GPCRs.